The FDA approved three significant cancer therapies between October 2025 and May 2026, including Enhertu for HER2-positive early-stage breast cancer, Zepzelca for extensive-stage small cell lung cancer, and Braftovi for BRAF-mutant colorectal cancer.
Categories